• RDM* biotech/pharma
  • Founded in: 2003
  • Staff: 77
  • Techniques: Other
  • Indications:

    Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism, Endocrine, nutritional and metabolic diseases, Mental and behavioural disorders, Diseases of the nervous system, Diseases of the circulatory system

  • Topic: Human health
  • Cluster Membership: LISAvienna
  • Profile:

    AFFiRiS develops first-in-class antigen specific vaccines for the prevention and treatment of chronic illnesses. Our proprietary AFFITOME®-Technology delivers peptides that are optimized to mimic a target specific epitope, thereby inducing an antibody response that is cross-reactive to the original target. Our clinical stage projects focus on Atherosclerosis prevention targeting PCSK9 and Parkinson’s disease targeting alpha synuclein.

  • R&D:

    AFFiRiS is an innovative, Vienna based biotechnology company. Using its proprietary AFFITOME® technology, it is able to develop customized peptide-based vaccines, called AFFITOPES®, targeting chronic diseases with high market values and unmet medical needs. Indications include Alzheimer’s disease, Parkinson’s disease, Atherosclerosis, Diabetes and several Others. AFFITOPES® mimic the structure of particular natural epitopes in disease targets and are capable of evoking therapeutic antibody responses. AFFITOPE® -based vaccines can be used to induce a specific immune response against pathological species of a given antigen without inducing adverse side effects like autoimmunity. To achieve its goal of developing therapeutic vaccines without side effects, AFFiRiS does not rely on preclinical data only, but follows its own unique concept of clinical maturation – from scratch (the idea) to commercialization. This includes a short and fast pre-clinical phase, risk diversification through a pool of product candidates and the development of more than one vaccine for a given target structure.